Evaxion A's Comment on Sales, Marketing and Customers
Customers are subject to various federal and state healthcare laws and regulations affecting their business and financial arrangements. These include the United States federal Anti-Kickback Statute, federal civil and criminal false claims laws such as the civil False Claims Act, HIPAA and its amendments, the federal Physician Payments Sunshine Act under the Affordable Care Act, and federal consumer protection and unfair competition laws. These laws govern activities including solicitation and payment for referrals, submission of claims to federal healthcare programs like Medicare and Medicaid, protection of health information, transparency of payments to physicians and teaching hospitals, and marketplace conduct.
Breakthrough in Cancer Research: Evaxion to Unveil Promising Phase 2 Trial Results of AI-Powered Vaccine at ESMO Congress 2025 COPENHAGEN, Denmark, October 13, 2025 In a promising leap forward in the fight against cancer, Evaxion A/S (NASDAQ: EVAX), a pioneering clinical-stage TechBio company, is set to present a significant breadth of data from its phase 2 trial of the AI-designed personalized cancer vaccine, EVX-01. The highly anticipated presentation is scheduled for the upcoming European Society for Medical Oncology (ESMO) Congress 2025, taking place in Berlin, Germany, from 17 to 21 October.Evaxion has captured the biotech world’s attention by harnessing the transformative power of AI-Immunology to ...
Evaxion A/S Finalizes Strategic Debt-to-Equity Conversion with European Investment Bank COPENHAGEN, Denmark, July 11, 2025 In a significant financial maneuver that signals its steadfast commitment to innovation and growth in the biotechnology sector, Evaxion A/S (NASDAQ: EVAX), a clinical-stage TechBio company capitalizing on its proprietary AI-Immunology platform to develop groundbreaking vaccines, has finalized an agreement with the European Investment Bank (EIB) to convert existing debt into equity. This strategic move marks a pivotal moment for Evaxion, enhancing its financial flexibility while fostering an environment conducive to accelerated research and development. Breaking Down the SignificanceThe...
Evaxion Biotech: Pioneering AI-Driven Vaccination Strategies in 2025 In a world grappling with unprecedented health challenges, the emergence of innovative biotechnologies has never been more critical. At the forefront of this revolution is Evaxion Biotech A/S, a Copenhagen-based clinical-stage TechBio company that is redefining the landscape of vaccine development through its disruptive AI-Immunology powered technologies. Founded with a vision to harness artificial intelligence in immunology, Evaxion is making waves in the biopharmaceutical industry. As we enter March 2025, the company s ambitious plans to present at multiple high-profile investor and scientific conferences illustrate its commitment to tran...
Progressing Towards Innovation: Evaxion Biotech Aims High with 2025 MilestonesCOPENHAGEN, Denmark, December 9, 2024 In a significant stride within the biotechnological sphere, Evaxion Biotech A/S (NASDAQ: EVAX) has unveiled its ambitious strategic milestones for the upcoming year of 2025. As a frontrunner in the field of TechBio, specifically focusing on the development of AI-immunology powered vaccines, Evaxion is cementing its position as a pioneer of groundbreaking medical advancements.Having successfully achieved nearly all the milestones set for 2024, Evaxion s announcement reiterates its unwavering commitment to continued innovation and strategic progression. This year has been transformative for Ev...
In a strategic move to strengthen its market presence, Evaxion Biotech A/S (NASDAQ: EVAX), a Copenhagen-based clinical-stage TechBio company renowned for its pioneering AI-Immunology powered vaccine development, has announced a planned adjustment to the ratio of its American Depositary Shares (ADSs) to its ordinary shares. Effective January 13, 2025, U.S. Eastern Time, this change will alter the ADS ratio from one ADS representing ten ordinary shares to one ADS representing fifty ordinary shares.This significant modification in the ADS structure is expected to provide several benefits for the company and its investors. By consolidating the number of ordinary shares represented by each ADS, Evaxion aims to en...
In a significant move that could reshape its financial standing and operational capacity, Evaxion Biotech A/S (NASDAQ: EVAX), a Copenhagen-based innovator in AI-powered vaccine technology, is actively negotiating a transformative agreement with the European Investment Bank (EIB). The proposed transaction involves converting approximately €3.5 million (around $3.7 million) of Evaxion s existing €7 million loan into an equity-type instrument. This strategic pivot not only reflects the company s commitment to robust capital management but also aligns with its long-term s in the competitive biotech arena. Key Facts:1. Company Background : Evaxion Biotech specializes in AI-immunology solutions, striving to r...
In the constantly evolving field of biopharmaceuticals, the integration of artificial intelligence (AI) in drug development has emerged as a pivotal trend. Evaxion Biotech, a pioneer in AI-immunology platforms, has made significant strides in leveraging this technology to advance therapeutic strategies against various diseases. Recent clinical trials have strongly validated Evaxion s innovative platform, which aims to enhance personalized immunotherapies by harnessing the power of AI to predict and optimize immune responses.Throughout this month, however, Evaxion Biotech A shares have been underperforming relative to the broader market. Year to date, the company’s shares have declined by 57.26%, a stark co...
Evaxion Expands Strategic Partnership with MSD to Enhance AI-Driven Vaccine DevelopmentIn a significant advancement for vaccine innovation, Evaxion Biotech A/S, a clinical-stage TechBio company renowned for its pioneering work in AI-Immunology, has bolstered its collaboration with MSD (Merck and Co. Inc.) through a newly inked option and license agreement. Announced on September 26, 2024, from Evaxion’s headquarters in Copenhagen, Denmark, this agreement involves two preclinical vaccine candidates and underscores the growing significance of artificial intelligence in the realm of immunotherapy and vaccine design.The collaboration marks an important step for Evaxion as it navigates the competitive landscap...
In the ever-evolving landscape of cancer treatment, personalization has become a focal point for researchers and clinicians alike. Evaxion Biotech A/S, a pioneering company at the intersection of artificial intelligence and immunology, has recently announced encouraging one-year data from its Phase 2 trial of EVX-01, a vaccine designed specifically for individual cancer patients. This breakthrough brings us closer to a potentially transformative shift in how we approach cancer therapy, moving away from traditional methods towards more tailored, patient-centric solutions. Evaxion s Innovative Approach Evaxion was founded on the principle that advanced technology can innovate how we develop healthcare solution...
COPENHAGEN, Denmark September 9, 2024 Evaxion Biotech A/S, a pioneering clinical-stage TechBio company renowned for its expertise in AI-driven immunology, has announced significant progress in its vaccine development pipeline with the achievement of pre-clinical Proof-of-Concept for its mRNA Gonorrhea vaccine candidate, EVX-B2. This groundbreaking development comes amidst ongoing advancements in the company’s personalized cancer vaccine, EVX-01, which has also demonstrated promising results as per recent trials presented at significant medical conferences. Proof-of-Concept for EVX-B2 Gonorrhea VaccineIn the latest pre-clinical studies, Evaxion has shown that the EVX-B2 mRNA vaccine effectively triggers...
Evaxion A’s Comment on Sales, Marketing and Customers
Customers are subject to various federal and state healthcare laws and regulations affecting their business and financial arrangements. These include the United States federal Anti-Kickback Statute, federal civil and criminal false claims laws such as the civil False Claims Act, HIPAA and its amendments, the federal Physician Payments Sunshine Act under the Affordable Care Act, and federal consumer protection and unfair competition laws. These laws govern activities including solicitation and payment for referrals, submission of claims to federal healthcare programs like Medicare and Medicaid, protection of health information, transparency of payments to physicians and teaching hospitals, and marketplace conduct.
Sources:
Evaxion A’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Evaxion A’s corporate clients.
For your research, we’ve provided 9 tables on Evaxion A corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
